OptimizeRx Corp
No SEC Form 4 filings for $OPRX in the last 30 days.
See all $OPRX insider activity →OptimizeRx (OPRX) reported Q2 2026 revenue of $20.5M, down 30% YoY due to lower-margin services and customer inactivity. Adjusted EBITDA was $4.9M. Full-year guidance was reaffirmed: $95M-$100M revenue and $21M-$25M adjusted EBITDA. AI software revenue grew 25% YoY. Cash and cash equivalents were $24.1M, with debt reduced to $19.7M. Management highlighted strategic shifts and leadership transitions. (350 characters)
OptimizeRx (NASDAQ:OPRX) reported Q2 2026 results with revenue down 30% year over year to $20.5 million. Net revenue retention fell to 90% and a major client generated no revenue. The firm cited $1.7 million severance, a $0.7 million net loss, and adjusted EBITDA of $4.1 million. Debt paydown is prioritized; buybacks possible under a $10 million plan.
OptimizeRx Corp (OPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 oprxq22026earningsrelease.htm EX-99.1 Document OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Q2 revenue totals $20.5 million - Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively - Reaffirms
Over the past 7 days, alphai's AI scored 1 news story mentioning OPRX (OptimizeRx Corp). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent OPRX coverage spans financial news, earnings and corporate actions.
Earnings beat expectations and guidance reaffirmed, indicating continued margin expansion.
Earnings call highlights point to near-term revenue pressure from top-account churn, partially offset by DSP integration going live and debt-focused capital allocation.
The filing provides fresh quarterly results plus unchanged full-year guidance, with a balance-sheet improvement via completed debt refinancing and term-loan paydown.
The CMO appointment is a leadership change that may modestly improve execution on go-to-market and partnerships, but it does not disclose financial guidance or product milestones.
Product launch could improve client conversion metrics and drive incremental revenue, but the release provides no financial guidance or contract wins.
alphai scores every news story that mentions OPRX with an AI model for sentiment and relevance, and aggregates insider trades from OptimizeRx Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
OptimizeRx (OPRX) reported Q2 2026 revenue of $20.5M, down 30% YoY due to lower-margin services and customer inactivity. Adjusted EBITDA was $4.9M. Full-year guidance was reaffirmed: $95M-$100M revenue and $21M-$25M adjusted EBITDA. AI software revenue grew 25% YoY. Cash and cash equivalents were $24.1M, with debt reduced to $19.7M. Management highlighted strategic shifts and leadership transitions. (350 characters)
3 min readOptimizeRx (NASDAQ:OPRX) reported Q2 2026 results with revenue down 30% year over year to $20.5 million. Net revenue retention fell to 90% and a major client generated no revenue. The firm cited $1.7 million severance, a $0.7 million net loss, and adjusted EBITDA of $4.1 million. Debt paydown is prioritized; buybacks possible under a $10 million plan.
6 min readOptimizeRx Corp (OPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 oprxq22026earningsrelease.htm EX-99.1 Document OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Q2 revenue totals $20.5 million - Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively - Reaffirms
4 min readOptimizeRx Corp. (Nasdaq: OPRX) appointed Sarah Bast as Chief Marketing Officer. She has over two decades in pharmaceutical marketing, most recently as EVP, Investment Marketplace at Publicis Health Media, with expertise in point of care media and analytics. OptimizeRx said the role will lead marketing strategy and go-to-market initiatives to support product innovation and commercial growth.
3 min readOptimizeRx Corp. (Nasdaq: OPRX) launched CopayCue, an enhancement to its Financial Assistance platform that uses real-time, verified HCP prescribing-intent data to display brand copay/affordability offers within e-prescribing workflows. The company says its data shows 4–5% higher prescription lift vs EHR banners and 11.5% average lift for standalone programs.
3 min readOptimizeRx Corp (OPRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001448431 0001448431 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readOptimizeRx Corp (OPRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001448431 0001448431 2026-06-01 2026-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readOptimizeRx Corp (OPRX) recently reported better-than-expected quarterly earnings and announced a new share buyback program, bringing renewed attention to the digital health company. The company surpassed consensus estimates with EPS of $0.14 and revenue of $19.84 million. OptimizeRx operates a digital health network connecting pharmaceutical manufacturers, payers, and healthcare providers, leveraging its platform-based model to integrate with EHR systems and monetize access for life sciences companies.
3 min readOptimizeRx (OPRX) is projected to release its Q1 2026 earnings on Tuesday, May 12th, with analysts expecting diluted EPS of $0.01 and revenue of $18.353 million. The company's board recently authorized a $10.0 million share buyback, and institutional investors hold a significant portion of its stock. Despite recent trading down to $6.59, analysts have a "Moderate Buy" consensus rating with a $17.57 price target.
2 min readThis page provides access to Optimizerx (OPRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material events, along with AI-powered summaries and impact analysis. Recent filings covered executive compensation, Q2 2025 financial results showing significant revenue growth, and a change in the board of directors. The platform offers detailed financial insights and regulatory document access for investors.
4 min read
